Strategic Blueprint LLC Has $335,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Posted by Defense World Staff on Jul 20th, 2023

Gilead Sciences logo Strategic Blueprint LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 11.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,034 shares of the biopharmaceutical company’s stock after buying an additional 414 shares during the period. Strategic Blueprint LLC’s holdings in Gilead Sciences were worth $335,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 23,848,477 shares of the biopharmaceutical company’s stock valued at $2,044,282,000 after acquiring an additional 244,886 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Morgan Stanley raised its stake in shares of Gilead Sciences by 11.5% during the 4th quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after purchasing an additional 1,780,489 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after buying an additional 6,410,047 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 14.8% in the third quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock valued at $951,350,000 after buying an additional 1,987,058 shares in the last quarter. 81.59% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.9 %

NASDAQ GILD opened at $78.96 on Thursday. The company has a market cap of $98.49 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.38. Gilead Sciences, Inc. has a 1-year low of $59.27 and a 1-year high of $89.74. The company has a current ratio of 1.28, a quick ratio of 1.13 and a debt-to-equity ratio of 1.10. The company has a 50 day moving average of $77.46 and a 200-day moving average of $80.94.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.26). Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The company had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $6.33 billion. During the same quarter in the previous year, the company posted $2.12 earnings per share. The business’s revenue was down 3.6% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 6.71 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 29th. Stockholders of record on Thursday, June 15th were given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 3.80%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s payout ratio is presently 67.72%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GILD. Morgan Stanley upped their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 12th. BMO Capital Markets reduced their price target on Gilead Sciences from $100.00 to $95.00 in a report on Tuesday. Barclays dropped their price objective on Gilead Sciences from $84.00 to $81.00 in a research note on Tuesday, July 11th. Cantor Fitzgerald reduced their target price on Gilead Sciences from $85.00 to $80.00 in a research note on Wednesday. Finally, StockNews.com initiated coverage on Gilead Sciences in a report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.10.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 1,485 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total value of $114,196.50. Following the transaction, the insider now directly owns 29,402 shares of the company’s stock, valued at $2,261,013.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.21% of the stock is currently owned by insiders.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.